CN108350041A - 修饰的炭疽毒素保护性抗原 - Google Patents

修饰的炭疽毒素保护性抗原 Download PDF

Info

Publication number
CN108350041A
CN108350041A CN201680062198.3A CN201680062198A CN108350041A CN 108350041 A CN108350041 A CN 108350041A CN 201680062198 A CN201680062198 A CN 201680062198A CN 108350041 A CN108350041 A CN 108350041A
Authority
CN
China
Prior art keywords
amino acid
ser
asn
leu
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680062198.3A
Other languages
English (en)
Chinese (zh)
Inventor
刘士辉
斯蒂芬·H·莱普拉
托马斯·H·巴格
亚力山大·N·韦恩
黛安·E·彼得斯
刘洁
陈光华
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United States Department of Health and Human Services
Original Assignee
United States Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United States Department of Health and Human Services filed Critical United States Department of Health and Human Services
Publication of CN108350041A publication Critical patent/CN108350041A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/07—Bacillus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
    • C07K14/325—Bacillus thuringiensis crystal peptides, i.e. delta-endotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201680062198.3A 2015-08-27 2016-08-25 修饰的炭疽毒素保护性抗原 Pending CN108350041A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562210771P 2015-08-27 2015-08-27
US62/210,771 2015-08-27
US201662323218P 2016-04-15 2016-04-15
US62/323,218 2016-04-15
PCT/US2016/048706 WO2017035359A1 (en) 2015-08-27 2016-08-25 Modified anthrax toxin protective antigen

Publications (1)

Publication Number Publication Date
CN108350041A true CN108350041A (zh) 2018-07-31

Family

ID=56943920

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680062198.3A Pending CN108350041A (zh) 2015-08-27 2016-08-25 修饰的炭疽毒素保护性抗原

Country Status (7)

Country Link
US (1) US10835593B2 (cg-RX-API-DMAC7.html)
EP (1) EP3341393B1 (cg-RX-API-DMAC7.html)
JP (1) JP6865211B2 (cg-RX-API-DMAC7.html)
KR (1) KR20180073555A (cg-RX-API-DMAC7.html)
CN (1) CN108350041A (cg-RX-API-DMAC7.html)
AU (1) AU2016311429C1 (cg-RX-API-DMAC7.html)
WO (1) WO2017035359A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117343942A (zh) * 2023-12-06 2024-01-05 南京市食品药品监督检验院 一种pagA重组蛋白及其制备方法

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180073555A (ko) 2015-08-27 2018-07-02 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 변형된 탄저균 독소 방어 항원
CA3119599A1 (en) 2018-11-16 2020-05-22 Rapa Therapeutics, Llc Als treatment using induced regulatory t (itreg) cells
EP4150060A4 (en) * 2020-05-13 2024-06-19 Rapa Therapeutics, LLC TREATMENT OR PREVENTION OF PRO-INFLAMMATORY DISEASES OR CONDITIONS USING INDUCED REGULATORY T CELLS (IT)
JP7648075B2 (ja) * 2020-11-27 2025-03-18 株式会社ダイセル 融合タンパク質

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7601351B1 (en) * 2002-06-26 2009-10-13 Human Genome Sciences, Inc. Antibodies against protective antigen
WO2014134187A1 (en) * 2013-02-26 2014-09-04 The Regents Of The University Of California Compositions and methods for the treatment of cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1214340B1 (en) 1999-09-24 2004-11-24 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Mutated anthrax toxin protective antigen proteins that specifically target cells containing high amounts of cell-surface metalloproteinases or plasminogen activator receptors
WO2005090393A2 (en) * 2004-02-09 2005-09-29 The Government Of The United States, As Represented By The Secretary Of Health And Human Services Multimeric protein toxins to target cells having multiple identifying characteristics
US20100168012A1 (en) 2006-12-14 2010-07-01 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Human cancer therapy using engineered matrix metalloproteinase-activated anthrax lethal toxin that targets tumor vasculatuture
CN101215568B (zh) 2008-01-18 2010-06-23 畿晋庆三联(北京)生物技术有限公司 抗炭疽多肽及其应用与制备方法
US9890369B2 (en) 2013-06-20 2018-02-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cytolethal distending toxin subunit B conjugated or fused to Bacillus anthracis toxin lethal factor
SG11201602012RA (en) 2013-09-25 2016-04-28 Pronutria Inc Compositions and formulations for maintaining and increasing muscle mass, strength, and performance and methods of production and use thereof
KR20180073555A (ko) 2015-08-27 2018-07-02 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 변형된 탄저균 독소 방어 항원

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7601351B1 (en) * 2002-06-26 2009-10-13 Human Genome Sciences, Inc. Antibodies against protective antigen
WO2014134187A1 (en) * 2013-02-26 2014-09-04 The Regents Of The University Of California Compositions and methods for the treatment of cancer

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DIANE E. PETERS等: "Comparative toxicity and efficacy of engineered anthrax lethal toxin variants with broad anti-tumor activities", 《TOXICOLOGY AND APPLIED PHARMACOLOGY》 *
M. J. ROSOVITZ等: "Alanine-scanning Mutations in Domain 4 of Anthrax Toxin Protective Antigen Reveal Residues Important for Binding to the Cellular Receptor and to a Neutralizing Monoclonal Antibody", 《THE JOURNAL OF BIOLOGICAL CHEMISTRY》 *
MICHAEL MOUREZ等: "Mapping dominant-negative mutations of anthrax protective antigen by scanning mutagenesis", 《PNAS》 *
NONE: "UniProtKB-S5M0J7", 《UNIPROT DATABASE》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117343942A (zh) * 2023-12-06 2024-01-05 南京市食品药品监督检验院 一种pagA重组蛋白及其制备方法
CN117343942B (zh) * 2023-12-06 2024-02-13 南京市食品药品监督检验院 一种pagA重组蛋白及其制备方法

Also Published As

Publication number Publication date
JP2018527926A (ja) 2018-09-27
EP3341393A1 (en) 2018-07-04
US10835593B2 (en) 2020-11-17
KR20180073555A (ko) 2018-07-02
AU2016311429A1 (en) 2018-04-19
WO2017035359A1 (en) 2017-03-02
AU2016311429C1 (en) 2021-10-07
US20180250376A1 (en) 2018-09-06
JP6865211B2 (ja) 2021-04-28
AU2016311429B2 (en) 2021-07-08
CA2996767A1 (en) 2017-03-02
EP3341393B1 (en) 2021-03-03

Similar Documents

Publication Publication Date Title
EP3341393B1 (en) Modified anthrax toxin protective antigen
CN100488981C (zh) 含有蛋白酶激活序列的气单胞菌溶素原及其应用
CN1195849C (zh) April-具有生长效应的新的蛋白质
KR100607609B1 (ko) Il-2 선택성 작용제 및 길항제
US20190328838A1 (en) Compositions comprising il-2 fusion proteins and methods for treating neoplasia
US8388933B2 (en) Multimeric protein toxins to target cells having multiple identifying characteristics
EP2130919A1 (en) IL-21 antagonists
KR20150035587A (ko) 그람 양성 박테리아에 대한 박테리오파지 리신과 항생제의 병용물
US20100135901A1 (en) Combination therapy
JP7744621B2 (ja) 切断されたモルモットl-アスパラギナーゼバリアントおよび使用の方法
CN102341407A (zh) 作为补体抑制剂的经修饰的omci
RO120919B1 (ro) Proteină hematopoietină, moleculă de acid nucleiccare o codifică, compoziţie farmaceutică şi utilizarea proteinei
CA2996767C (en) Modified anthrax toxin protective antigen
AU2015243297A1 (en) Poxviral oncolytic vectors
WO2023155872A1 (zh) 一种实现生物活性分子其活性控释和缓释的方法及药物应用
JP4273234B2 (ja) チオレドキシン改変体
CN1267450C (zh) 新型人肿瘤坏死因子突变蛋白及其制法和用途
CN117417429A (zh) 肿瘤微环境激活的细胞因子及其应用
HK1033956A1 (en) Genetically modified tumor-targeted bacteria with reduced virulence
HK1033956B (en) Genetically modified tumor-targeted bacteria with reduced virulence
Kreitman IBC’s International Conference on novel therapeutic proteins for oncology (drug discovery and development)
CN1913913A (zh) Cab分子
CN1167502A (zh) 人dna连接酶iii
WO2010062982A1 (en) Tumor-targeting co2-resistant salmonella

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180731